Cancer Diagnostics Market 2019 Key highlights, Segmentation, Overview and Forecast

The Research Report on Cancer Diagnostics Market Consist 89 market data tables and 37 figures spread through 197 pages and in-depth TOC, which covers Global Market overview, Major Key Players detailed Analysis, market opportunities, market risk, forecast for the next five years, major driving factors for the market as well as detailed analysis for CAGR, scope, research findings, leading key players marketing strategy to acquire major market in the form of revenue.

The cancer diagnostics market is highly competitive with many big and small players operating in different market segments.

Technological advancements in various fields such as biomarkers, imaging, biopsy, endoscopy; growing number of cancer cases, rapidly rise in geriatric population, awareness initiatives by governments, and increasing government funding are major factors driving the market growth. However, high capital investment and low benefit-cost ratio of biomarkers and dearth of skilled professionals pose restraints to the growth of this market. Improving healthcare infrastructure in emerging countries and growing demand of companion diagnostics offer growth opportunities for this market.

The global cancer diagnostics market is segmented based on technology, application, and region.

Download PDF (cancer diagnostics):

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186559121

The platform-based technology is further segmented into next-generation sequencing, microarrays, PCR, flow cytometry, in situ hybridization, immunohistochemistry, and others. Instrument-based cancer diagnostics is further segmented into imaging systems and biopsy.

Market-by Application

·         Breast Cancer

·         Lung Cancer

·         Colorectal Cancer

·         Melanoma

Cancer Diagnostics Market, by Product

# Platform-based

-          Next-generation Sequencing

-          Microarrays

-          PCR

-          Flow Cytometry

# Instrument-based

-          Imaging Instruments

-          Ultrasound

-          Mammography

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186559121

Based on region, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises Latin America, Pacific countries, and Middle East and Africa. North America is expected to account for the largest share in the cancer diagnostics market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for the companies operating in the market.

Some of the major players in the global market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V.  (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.)

European Healthcare EDI Market 2018 Analysis, Key Players, Size, Growth Rate and Forecast

EDI is increasingly being adopted in the European Healthcare EDI Market; this industry is expected to register significant growth due to greater uptake of EDI solutions among pharmaceuticals and medical device companies owing to various advantages such as reduction in the administration costs, reduced errors, pricing pressure, and lower profit margins. Moreover, the increasing number of government initiatives toward the implementation of IT in the healthcare industry is estimated to propel the demand for healthcare IT solutions, which in turn will drive the healthcare EDI market.

However, high cost of EDI implementation, challenges in management of EDI, security concerns of the data and restricted investments in healthcare EDI by hospitals present challenges to the overall growth of the market. The increasing use of EDI in healthcare manufacturing & distribution industry and gradual acceptance of mobile EDI are the major trends in the EDI market.

In this report, the European Healthcare EDI Market is segmented based on type of transaction, type of purchasing organization, and region. ORDERS was the most preferred transaction type, followed by INVOIC in European healthcare system. In terms of volume, in 2015, approximately 51.2 million purchase orders were generated by hospitals in Germany through EDI. The increasing number of hospitals in Europe adopting EDI solutions especially in supply chain management due reduced errors enabling operational benefits, less errors, faster transaction processing, and various government initiatives are the key factors contributing to the growth of healthcare EDI market in Europe.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93400242

The European Healthcare EDI Market is growing at a fast pace. Europe is one of the major markets for the use of EDI in healthcare supply chain. Pharmaceutical wholesalers were early adopters of EDI in Europe, and currently process nearly 92%–95% of their orders through EDI. Due to growing competition and decreasing profit margins, pharmaceutical companies and medical device manufacturers in Europe are under increasing pressure to implement EDI systems that help them cut operating costs and remain competitive and profitable. ORDERS, DESADV, and INVOIC are the most preferred EDI transaction types for supply chain management in hospitals across Europe.

EDI primarily focuses on the electronic exchange of business transactions such as purchase orders, shipment authorizations, shipment acknowledgements, advanced shipment notices, or invoices. EDI provides a fast, secure, and easy exchange of information between healthcare organizations. Most of the hospitals in Europe are focusing on deploying a full suite of electronic processes with automated methods to track the complete process of purchase order purchase order acknowledgement, invoice creation/matching, and processing to the accounts payable system.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=93400242

Geographically, the European Healthcare EDI Market is analyzed at the country level, comprising Benelux, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, and the U.K. Germany, France, Denmark, Sweden are expected to witness a high penetration rate for healthcare EDI in coming years owing to the rising geriatric population, increasing government funding and initiatives, improving healthcare infrastructure, increasing demand for quality healthcare at low costs, and presence of major companies in these regions.

Bayer AG, Pfizer Inc., GlaxoSmithKline PLC, and Abbott Laboratories are the EDI technology leaders in the pharmaceutical and manufacturing sector in Europe.